首页> 外文期刊>Clinical and Translational Medicine >Lactobacillus lactis and Pediococcus pentosaceus‐driven reprogramming of gut microbiome and metabolome ameliorates the progression of non‐alcoholic fatty liver disease
【24h】

Lactobacillus lactis and Pediococcus pentosaceus‐driven reprogramming of gut microbiome and metabolome ameliorates the progression of non‐alcoholic fatty liver disease

机译:<斜体切换=“是”>乳杆菌乳房和<斜体切换=“是”> Pediococcus pentosaceus -drive肠道微生物组和代谢物的重新编程改善了非酒精性脂肪肝病的进展

获取原文
           

摘要

Background Although microbioa‐based therapies have shown putative effects on the treatment of non‐alcoholic fatty liver disease (NAFLD), it is not clear how microbiota‐derived metabolites contribute to the prevention of NAFLD. We explored the metabolomic signature of Lactobacillus lactis and Pediococcus pentosaceus in NAFLD mice and its association in NAFLD patients. Methods We used Western diet‐induced NAFLD mice, and L. lactis and P. pentosaceus were administered to animals in the drinking water at a concentration of 10 ~(9) CFU/g for 8?weeks. NAFLD severity was determined based on liver/body weight, pathology and biochemistry markers. Caecal samples were collected for the metagenomics by 16S rRNA sequencing. Metabolite profiles were obtained from caecum, liver and serum. Human stool samples (healthy control [ n ?=?22] and NAFLD patients [ n ?=?23]) were collected to investigate clinical reproducibility for microbiota‐derived metabolites signature and metabolomics biomarker. Results L. lactis and P. pentosaceus supplementation effectively normalized weight ratio, NAFLD activity score, biochemical markers, cytokines and gut‐tight junction. While faecal microbiota varied according to the different treatments, key metabolic features including short chain fatty acids (SCFAs), bile acids (BAs) and tryptophan metabolites were analogously restored by both probiotic supplementations. The protective effects of indole compounds were validated with in vitro and in vivo models, including anti‐inflammatory effects. The metabolomic signatures were replicated in NAFLD patients, accompanied by the comparable levels of Firmicutes / Bacteroidetes ratio, which was significantly higher (4.3) compared with control (0.6). Besides, the consequent biomarker panel with six stool metabolites (indole, BAs, and SCFAs) showed 0.922 (area under the curve) in the diagnosis of NAFLD. Conclusions NAFLD progression was robustly associated with metabolic dys‐regulations in the SCFAs, bile acid and indole compounds, and NAFLD can be accurately diagnosed using the metabolites. L. lactis and P. pentosaceus ameliorate NAFLD progression by modulating gut metagenomic and metabolic environment, particularly tryptophan pathway, of the gut‐liver axis. Diet with the L. lactis and P. pentosaceus inhibited NAFLD progression via normalization of metabolites including indoles, SCFAs, or BA composition, which in turn was achieved by modulation of gut microbiota composition and production of anti‐inflammatory metabolites.
机译:背景技术虽然基于微生物的疗法表明了对非酒精脂肪肝疾病(NAFLD)的治疗(NAFLD)的疗效,但目前尚不清楚Microbiota衍生的代谢物如何有助于预防NAFLD。我们探讨了在NAFLD小鼠的乳酸乳杆菌和Pediococcus Pentosaceus的代谢组织特征及其在NAFLD患者的关联。方法使用西方饮食诱导的NAFLD小鼠,L.乳酸乳裂和P.Pentosaceus以10〜(9)CFU / g的浓度为8〜(9)CFU / g。基于肝脏/体重,病理和生物化学标记来确定NAFLD严重程度。通过16S rRNA测序收集剖腹产的菌样本。从盲肠,肝脏和血清中获得代谢物型材。收集人粪便样品(健康对照[N?=β22]和NAFLD患者[N?=β3])以研究微生物群衍生的代谢物签名和代谢组学生物标志物的临床再现性。结果L.乳酸乳裂藻和P. Pentosaceus补充有效归一化重量比,NAFLD活动评分,生化标志物,细胞因子和肠间隙。虽然粪便微生物群根据不同的处理而变化,但通过益生菌补充类似地恢复包括短链脂肪酸(SCFA),胆汁酸(BAS)和色氨酸代谢物的关键代谢特征。吲哚化合物的保护作用在体外和体内模型中验证,包括抗炎作用。在NAFLD患者中复制代谢物签名,伴随着与对照(0.6)相比显着高(4.3)的常规/菌丝比的相当水平。此外,随着六种粪便代谢物(吲哚,BAS和SCFA)的结果,患有六种粪便代谢物(吲哚,BAS和SCFA)的生物标志物组在NAFLD的诊断中显示了0.922(曲线下的区域)。结论NAFLD进化较强烈地与SCFA中的代谢性能 - 法规相关,胆汁酸和吲哚化合物,可以使用代谢物准确地诊断NAFLD。 L.乳酸乳裂和P. Pentosaceus通过调节肠道组和代谢环境,特别是色氨酸途径,肠道肝轴来改善NAFLD进展。用L.乳酸乳裂和P. pentosaceus饮食通过代谢物的标准化抑制NAFLD进展,包括吲哚,SCFA或BA组合物,其又通过调节肠道微生物A组成和抗炎代谢物的产生来实现。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号